{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:20Z","timestamp":1792783520533,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The InFLAMES Flagship Program of the Research Council of Finland","award":["374291"],"award-info":[{"award-number":["374291"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The InFLAMES Flagship Program of the Research Council of Finland","award":["337530"],"award-info":[{"award-number":["337530"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The InFLAMES Flagship Program of the Research Council of Finland","award":["357910"],"award-info":[{"award-number":["357910"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The InFLAMES Flagship Program of the Research Council of Finland","award":["358823"],"award-info":[{"award-number":["358823"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["#220026"],"award-info":[{"award-number":["#220026"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01044-5","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:11Z","timestamp":1790754131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct04239820","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0982-7514","authenticated-orcid":false,"given":"Olli","family":"Rajalehto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2670","authenticated-orcid":false,"given":"Markus","family":"Matilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-2549","authenticated-orcid":false,"given":"Jussi","family":"Lehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4707-7277","authenticated-orcid":false,"given":"Eveliina","family":"Honkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-9677","authenticated-orcid":false,"given":"Mikko","family":"Koivum\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-0945","authenticated-orcid":false,"given":"Saara","family":"Wahlroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3591-0963","authenticated-orcid":false,"given":"Johan","family":"Rajander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2798-9982","authenticated-orcid":false,"given":"Olavi","family":"Misin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5689-052X","authenticated-orcid":false,"given":"Amelie","family":"Luoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-8630","authenticated-orcid":false,"given":"Sini","family":"Laaksonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-6917","authenticated-orcid":false,"given":"Anna","family":"Vuorimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-2931","authenticated-orcid":false,"given":"Marcus","family":"Sucksdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5976","authenticated-orcid":false,"given":"Maija","family":"Saraste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9751-5881","authenticated-orcid":false,"given":"Laura","family":"Airas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326. https:\/\/doi.org\/10.1056\/NEJMoa0902533.","journal-title":"N Engl J Med"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2147\/CLEP.S480525","volume":"16","author":"J Hillert","year":"2024","unstructured":"Hillert J, Butzkueven H, Magyari M, et al. Harmonized data quality indicators maintain data quality in long-term safety studies using multiple sclerosis registries\/data sources: experience from the CLARION study. Clin Epidemiol. 2024;16:717\u201332. https:\/\/doi.org\/10.2147\/CLEP.S480525.","journal-title":"Clin Epidemiol"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase\u00a03 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78:558\u201367. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405.","journal-title":"JAMA Neurol"},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77:1132\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568.","journal-title":"JAMA Neurol"},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/WCO.0000000000001045","volume":"35","author":"L Airas","year":"2022","unstructured":"Airas L, Yong VW. Microglia in multiple sclerosis\u2014pathogenesis and imaging. Curr Opin Neurol. 2022;35:299\u2013306. https:\/\/doi.org\/10.1097\/WCO.0000000000001045.","journal-title":"Curr Opin Neurol"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120\u201331. https:\/\/doi.org\/10.2165\/00003088-199732020-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28. https:\/\/doi.org\/10.1097\/WNF.0b013e318204cd90.","journal-title":"Clin Neuropharmacol"},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cei.13473","volume":"201","author":"L\u00d8 J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen L\u00d8, Hyrlov KH, Elkjaer ML, et al. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020;201:328\u201340. https:\/\/doi.org\/10.1111\/cei.13473.","journal-title":"Clin Exp Immunol"},{"key":"1044_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108571","volume":"105","author":"F Aybar","year":"2022","unstructured":"Aybar F, Julia Perez M, Silvina Marcora M, et al. 2-Chlorodeoxyadenosine (cladribine) preferentially inhibits the biological activity of microglial cells. Int Immunopharmacol. 2022;105:108571. https:\/\/doi.org\/10.1016\/j.intimp.2022.108571.","journal-title":"Int Immunopharmacol"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11481-012-9387-7","volume":"7","author":"V Singh","year":"2012","unstructured":"Singh V, Voss EV, B\u00e9nardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (cladribine) on primary rat microglia. J Neuroimmune Pharmacol. 2012;7:939\u201350. https:\/\/doi.org\/10.1007\/s11481-012-9387-7.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1044_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106546","volume":"100","author":"G Guido","year":"2025","unstructured":"Guido G, Preziosa P, Filippi M, Rocca MA. TSPO PET in multiple sclerosis: emerging insights into pathophysiology, prognosis, and treatment monitoring. Mult Scler Relat Disord. 2025;100:106546. https:\/\/doi.org\/10.1016\/j.msard.2025.106546.","journal-title":"Mult Scler Relat Disord"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1093\/brain\/awz287","volume":"142","author":"E Nutma","year":"2019","unstructured":"Nutma E, Stephenson JA, Gorter RP, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain. 2019;142:3440\u201355. https:\/\/doi.org\/10.1093\/brain\/awz287.","journal-title":"Brain"},{"key":"1044_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000443","volume":"5","author":"E Rissanen","year":"2018","unstructured":"Rissanen E, Tuisku J, Vahlberg T, et al. Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e443. https:\/\/doi.org\/10.1212\/NXI.0000000000000443.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1044_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200133","volume":"10","author":"E Polvinen","year":"2023","unstructured":"Polvinen E, Matilainen M, Nylund M, Sucksdorff M, Airas LM. TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200133. https:\/\/doi.org\/10.1212\/NXI.0000000000200133.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1044_CR16","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awaa275","volume":"143","author":"M Sucksdorff","year":"2020","unstructured":"Sucksdorff M, Matilainen M, Tuisku J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain. 2020;143:3318\u201330. https:\/\/doi.org\/10.1093\/brain\/awaa275.","journal-title":"Brain"},{"key":"1044_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000574","author":"M Sucksdorff","year":"2019","unstructured":"Sucksdorff M, Tuisku J, Matilainen M, et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm. 2019. https:\/\/doi.org\/10.1212\/NXI.0000000000000574.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1044_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2017.04.008","volume":"15","author":"UW Kaunzner","year":"2017","unstructured":"Kaunzner UW, Kang Y, Monohan E, et al. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Mult Scler Relat Disord. 2017;15:27\u201333. https:\/\/doi.org\/10.1016\/j.msard.2017.04.008.","journal-title":"Mult Scler Relat Disord"},{"key":"1044_CR19","doi-asserted-by":"publisher","unstructured":"Chitnis T, Singhal T, Zurawski J, et al. Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS. medRxiv:2025.04.30.25326602. 2025 [cited 2025 Oct 28]. https:\/\/doi.org\/10.1101\/2025.04.30.25326602.","DOI":"10.1101\/2025.04.30.25326602"},{"key":"1044_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00415-011-6337-x","volume":"259","author":"JN Ratchford","year":"2012","unstructured":"Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012;259:1199\u2013205. https:\/\/doi.org\/10.1007\/s00415-011-6337-x.","journal-title":"J Neurol"},{"key":"1044_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mrm.25358","volume":"73","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu T. Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med. 2015;73:82\u2013101. https:\/\/doi.org\/10.1002\/mrm.25358.","journal-title":"Magn Reson Med"},{"key":"1044_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2017","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017;17:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"1044_CR23","unstructured":"Mavenclad | European Medicines Agency (EMA). 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. Accessed 1 July 2025."},{"key":"1044_CR24","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u20131444. https:\/\/doi.org\/10.1212\/WNL.33.11.1444.","journal-title":"Neurology"},{"key":"1044_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.5555\/uri:pii:0003999388900093","volume":"69","author":"DE Goodkin","year":"1988","unstructured":"Goodkin DE, Hertsguard D, Seminary J. Upper extremity function in multiple sclerosis: Improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil Elsevier. 1988;69:850\u20134. https:\/\/doi.org\/10.5555\/uri:pii:0003999388900093.","journal-title":"Arch Phys Med Rehabil Elsevier"},{"key":"1044_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1212\/WNL.49.5.1419","volume":"49","author":"SR Schwid","year":"1997","unstructured":"Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology. 1997;49:1419\u201324. https:\/\/doi.org\/10.1212\/WNL.49.5.1419.","journal-title":"Neurology"},{"key":"1044_CR27","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2967\/jnumed.116.183020","volume":"58","author":"M Sucksdorff","year":"2017","unstructured":"Sucksdorff M, Rissanen E, Tuisku J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med. 2017;58:1646\u201351. https:\/\/doi.org\/10.2967\/jnumed.116.183020.","journal-title":"J Nucl Med"},{"key":"1044_CR28","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1016\/j.neuroimage.2011.11.032","volume":"59","author":"P Schmidt","year":"2012","unstructured":"Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012;59:3774\u201383. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.11.032.","journal-title":"Neuroimage"},{"key":"1044_CR29","doi-asserted-by":"publisher","first-page":"fcab301","DOI":"10.1093\/braincomms\/fcab301","volume":"4","author":"M Nylund","year":"2022","unstructured":"Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, Airas L. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18\u00a0kDa translocator protein-PET. Brain Commun. 2022;4:fcab301. https:\/\/doi.org\/10.1093\/braincomms\/fcab301.","journal-title":"Brain Commun"},{"key":"1044_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2023-331051","volume":"94","author":"M Saraste","year":"2023","unstructured":"Saraste M, Matilainen M, Vuorimaa A, et al. Association of serum neurofilament light with microglial activation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;94:698\u2013706. https:\/\/doi.org\/10.1136\/jnnp-2023-331051.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1044_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00004728-200105000-00022","volume":"25","author":"SM Smith","year":"2001","unstructured":"Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001;25:466.","journal-title":"J Comput Assist Tomogr"},{"key":"1044_CR32","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41591-025-03625-7","volume":"31","author":"L Klotz","year":"2025","unstructured":"Klotz L, Smolders J, Lehto J, et al. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nat Med. 2025;31:2016\u201326. https:\/\/doi.org\/10.1038\/s41591-025-03625-7.","journal-title":"Nat Med"},{"key":"1044_CR33","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/mrm.26946","volume":"79","author":"Z Liu","year":"2018","unstructured":"Liu Z, Spincemaille P, Yao Y, Zhang Y, Wang Y. MEDI+0: morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping. Magn Reson Med. 2018;79:2795\u2013803. https:\/\/doi.org\/10.1002\/mrm.26946.","journal-title":"Magn Reson Med"},{"key":"1044_CR34","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/brain\/awae013","volume":"147","author":"F Bagnato","year":"2024","unstructured":"Bagnato F, Sati P, Hemond CC, et al. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain. 2024;147:2913\u201333. https:\/\/doi.org\/10.1093\/brain\/awae013.","journal-title":"Brain"},{"key":"1044_CR35","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/ene.15834","volume":"30","author":"J Lehto","year":"2023","unstructured":"Lehto J, Nylund M, Matilainen M, et al. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis. Eur J Neurol. 2023;30:2365\u201375. https:\/\/doi.org\/10.1111\/ene.15834.","journal-title":"Eur J Neurol"},{"key":"1044_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340. https:\/\/doi.org\/10.1097\/00004647-199609000-00008.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1044_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03519-y","volume":"22","author":"M Nylund","year":"2025","unstructured":"Nylund M, Lehto J, Matilainen M, et al. Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis. J Neuroinflammation. 2025;22:200. https:\/\/doi.org\/10.1186\/s12974-025-03519-y.","journal-title":"J Neuroinflammation"},{"key":"1044_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70472","author":"MT Morch","year":"2026","unstructured":"Morch MT, Matilainen M, Baldrighi GN, Nylund M, Saraste M, Airas L. Baseline neuroinflammation stratifies TSPO-PET response to disease-modifying therapy in multiple sclerosis. Ann Clin Transl Neurol. 2026. https:\/\/doi.org\/10.1002\/acn3.70472.","journal-title":"Ann Clin Transl Neurol"},{"key":"1044_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121\u20133. https:\/\/doi.org\/10.1001\/archneur.1989.00520460115022.","journal-title":"Arch Neurol"},{"key":"1044_CR40","volume-title":"Multiple sclerosis quality of life inventory: a user\u2019s manual","author":"PG Ritvo","year":"1997","unstructured":"Ritvo PG, Fischer JS, Miller DM, Andrews H, Paty DW, LaRocca NG. Multiple sclerosis quality of life inventory: a user\u2019s manual. New York: National Multiple Sclerosis Society; 1997."},{"key":"1044_CR41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","volume":"124","author":"J Hobart","year":"2001","unstructured":"Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124:962\u201373. https:\/\/doi.org\/10.1093\/brain\/124.5.962.","journal-title":"Brain"},{"key":"1044_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"1044_CR43","unstructured":"R Core Team. R: a Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2023. https:\/\/www.R-project.org\/. Accessed 1 Sep 2026."},{"key":"1044_CR44","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s10072-023-06794-w","volume":"44","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh F, Mohamadi M, Rahmani S, et al. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;44:3045\u201357. https:\/\/doi.org\/10.1007\/s10072-023-06794-w.","journal-title":"Neurol Sci"},{"key":"1044_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12121595","volume":"12","author":"D Paolicelli","year":"2022","unstructured":"Paolicelli D, Ruggieri M, Manni A, et al. Real-life experience of the effects of cladribine tablets on lymphocyte subsets and serum neurofilament light chain levels in relapsing multiple sclerosis patients. Brain Sci. 2022;12:1595. https:\/\/doi.org\/10.3390\/brainsci12121595.","journal-title":"Brain Sci"},{"key":"1044_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044067","volume":"24","author":"M Seiberl","year":"2023","unstructured":"Seiberl M, Feige J, Hilpold P, et al. Serum neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting. Int J Mol Sci. 2023;24:4067. https:\/\/doi.org\/10.3390\/ijms24044067.","journal-title":"Int J Mol Sci"},{"key":"1044_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512189","author":"H Wiendl","year":"2025","unstructured":"Wiendl H, Barkhof F, Montalban X, et al. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1512189.","journal-title":"Front Immunol"},{"key":"1044_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.125681","volume":"480","author":"V Nicolella","year":"2026","unstructured":"Nicolella V, Varelli M, Fasano S, et al. Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis. J Neurol Sci. 2026;480:125681. https:\/\/doi.org\/10.1016\/j.jns.2025.125681.","journal-title":"J Neurol Sci"},{"key":"1044_CR49","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/13524585251313749","volume":"31","author":"A Achiron","year":"2025","unstructured":"Achiron A, Warszawer Y, Nissan Y, et al. Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: a longitudinal study. Mult Scler J. 2025;31:689\u201395. https:\/\/doi.org\/10.1177\/13524585251313749.","journal-title":"Mult Scler J"},{"key":"1044_CR50","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s00415-020-09740-4","volume":"267","author":"S Magon","year":"2020","unstructured":"Magon S, Tsagkas C, Gaetano L, et al. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. J Neurol. 2020;267:1536\u201346. https:\/\/doi.org\/10.1007\/s00415-020-09740-4.","journal-title":"J Neurol"},{"key":"1044_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2013.08.009","volume":"264","author":"A Musella","year":"2013","unstructured":"Musella A, Mandolesi G, Gentile A, et al. Cladribine interferes with IL-1\u03b2 synaptic effects in experimental multiple sclerosis. J Neuroimmunol. 2013;264:8\u201313. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.009.","journal-title":"J Neuroimmunol"},{"key":"1044_CR52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00210-011-0719-6","volume":"385","author":"K Jensen","year":"2012","unstructured":"Jensen K, Johnson LA, Jacobson PA, et al. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:519\u201325. https:\/\/doi.org\/10.1007\/s00210-011-0719-6.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1044_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/glia.22592","volume":"62","author":"L Luongo","year":"2014","unstructured":"Luongo L, Guida F, Imperatore R, et al. The A1 adenosine receptor as a new player in microglia physiology. Glia. 2014;62:122\u201332. https:\/\/doi.org\/10.1002\/glia.22592.","journal-title":"Glia"},{"key":"1044_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2","volume":"18","author":"BL Fiebich","year":"1996","unstructured":"Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia. 1996;18:152\u201360. https:\/\/doi.org\/10.1002\/(SICI)1098-1136(199610)18:2%3c152::AID-GLIA7%3e3.0.CO;2-2.","journal-title":"Glia"},{"key":"1044_CR55","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nn.3930","volume":"18","author":"AG Orr","year":"2015","unstructured":"Orr AG, Hsiao EC, Wang MM, et al. Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015;18:423\u201334. https:\/\/doi.org\/10.1038\/nn.3930.","journal-title":"Nat Neurosci"},{"key":"1044_CR56","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nn.2341","volume":"12","author":"AG Orr","year":"2009","unstructured":"Orr AG, Orr AL, Li X-J, Gross RE, Traynelis SF. Adenosine A2A receptor mediates microglial process retraction. Nat Neurosci. 2009;12:872\u20138. https:\/\/doi.org\/10.1038\/nn.2341.","journal-title":"Nat Neurosci"},{"key":"1044_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-026-03725-2","author":"D Marastoni","year":"2026","unstructured":"Marastoni D, Eccher C, Signori A, et al. The effect of cladribine tablets on intrathecal inflammation in relapsing\u2013remitting multiple sclerosis. J Neuroinflamm. 2026. https:\/\/doi.org\/10.1186\/s12974-026-03725-2.","journal-title":"J Neuroinflamm"},{"key":"1044_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106339","volume":"96","author":"M Marrodan","year":"2025","unstructured":"Marrodan M, Ya\u00f1ez P, Calandri IL, et al. Impact of oral Cladribine on paramagnetic rim lesions of Multiple Sclerosis patients. Mult Scler Relat Disord. 2025;96:106339. https:\/\/doi.org\/10.1016\/j.msard.2025.106339.","journal-title":"Mult Scler Relat Disord"},{"key":"1044_CR59","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ana.25877","volume":"88","author":"P Maggi","year":"2020","unstructured":"Maggi P, Sati P, Nair G, et al. Paramagnetic rim lesions are specific to multiple sclerosis: an international multicenter 3T MRI study. Ann Neurol. 2020;88:1034\u201342. https:\/\/doi.org\/10.1002\/ana.25877.","journal-title":"Ann Neurol"},{"key":"1044_CR60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41582-021-00537-1","volume":"17","author":"B Bodini","year":"2021","unstructured":"Bodini B, Tonietto M, Airas L, Stankoff B. Positron emission tomography in multiple sclerosis\u2014straight to the target. Nat Rev Neurol. 2021;17:663\u201375. https:\/\/doi.org\/10.1038\/s41582-021-00537-1.","journal-title":"Nat Rev Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01044-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01044-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:13Z","timestamp":1790754133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01044-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":60,"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01044-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"6 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olli Rajalehto has received support for conference participation and travel from Merck KGaA and research support from Maire Taponen Foundation and Turku University Hospital Foundation, and owns stocks of Orion Corporation; Markus Matilainen, Jussi Lehto, Eveliina Honkonen, Mikko Koivum\u00e4ki, Saara Wahlroos, Johan Rajander, Olavi Misin, Amelie Luoma, Sini Laaksonen, Anna Vuorimaa, and Marcus Sucksdorff report no disclosures relevant to the manuscript; Maija Saraste has received support for attending a meeting from Merck KGaA; Laura Airas has obtained compensation for lectures and advising from F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, and Sanofi-Genzyme S.A., and institutional research support from Sanofi-Genzyme S.A. and Merck KGaA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Hospital District of Southwest Finland approved the study, approval number 89\/1800\/2019. The study was registered on ClinicalTrials.gov (NCT04239820) on January 21, 2020. The study was conducted in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}